212P Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study

Autor:	S. Morganti, S. Gandini, E. Nicolo, E. Zattarin, C. Corti, A. Verrazzo, P.P.M. Berton Giachetti, C. Sposetti, M.G. Razeti, B. Taurelli Salimbeni, L. Boldrini, A. Carnevale Schianca, R. Caputo, C. Vernieri, E. Munzone, M. Lambertini, M. De Laurentiis, G. Viale, G. Curigliano, C. Criscitiello
Rok vydání:	2023
Předmět:	Cancer Research Oncology
Zdroj:	ESMO Open. 8:101401
ISSN:	2059-7029
DOI:	10.1016/j.esmoop.2023.101401
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::47edf11da36718df40e06a44b3e74f43 https://doi.org/10.1016/j.esmoop.2023.101401 Zobrazit plný text záznamu